NEW BRUNSWICK, N.J. — January 21, 2026 — Leads & Copy — Johnson & Johnson (NYSE: JNJ) has released its financial results for the fourth quarter and full year of 2025, with Chairman and CEO Joaquin Duato calling 2025 a “catapult year.” According to Duato, the company’s success was fueled by the strongest portfolio and pipeline in its history. The past year has ushered in an era of accelerated growth, propelled by medical innovation impacting oncology, immunology, neuroscience, cardiovascular, surgery, and vision.
In the fourth quarter, Johnson & Johnson reported sales of $24.564 billion, a 9.1% increase compared to $22.520 billion in 2024. Net earnings for the quarter reached $5.116 billion, a 49.1% jump from $3.431 billion in the previous year. The company’s diluted earnings per share (EPS) stood at $2.10, reflecting a 48.9% increase from $1.41 in 2024.
For the full year, the company reported sales of $94.193 billion, a 6.0% increase compared to $88.821 billion in 2024. Net earnings for the year amounted to $26.804 billion, a 90.6% increase from $14.066 billion in the previous year. Diluted EPS for the year was $11.03, up 90.5% from $5.79 in 2024.
Non-GAAP measures provide additional insights into Johnson & Johnson’s financial performance. Adjusted net earnings for the fourth quarter were $6.009 billion, a 21.5% increase from $4.946 billion in 2024, with adjusted diluted EPS at $2.46, a 20.6% increase. For the full year, adjusted net earnings were $26.215 billion, an 8.1% increase from $24.242 billion in 2024, with adjusted diluted EPS at $10.79, also an 8.1% increase. The company’s free cash flow is estimated to be ~$19.7 billion.
In the U.S., fourth-quarter sales reached $14.195 billion, a 7.5% increase. International sales totaled $10.369 billion, an 11.3% increase. For the full year, U.S. sales were $53.752 billion, a 6.9% increase, while international sales were $40.441 billion, a 5.0% increase.
Innovative Medicine segment sales for the fourth quarter were $15.763 billion, a 10.0% increase, and MedTech segment sales were $8.801 billion, a 7.5% increase. For the full year, Innovative Medicine sales totaled $60.401 billion, a 6.0% increase, and MedTech sales were $33.792 billion, a 6.1% increase.
For the full year 2025, Innovative Medicine operational sales grew by 5.3%, driven by oncology drugs like DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE, immunology drugs TREMFYA and SIMPONI/SIMPONI ARIA, and neuroscience drug SPRAVATO. MedTech operational sales grew by 5.4%, driven by electrophysiology products and Abiomed in Cardiovascular and wound closure products in General Surgery.
Johnson & Johnson has issued its full-year 2026 guidance, estimating adjusted operational sales to increase by 5.4% – 6.4%, operational sales to be between $99.5 billion and $100.5 billion, and reported sales to be between $100.0 billion and $101.0 billion. Adjusted operational EPS is projected to be between $11.28 and $11.48, while adjusted EPS is expected to be between $11.43 and $11.63.
Recent regulatory approvals include the FDA’s approval of AKEEGA, DARZALEX FASPRO, CAPLYTA and TRUFILL n‑BCA Liquid Embolic System and RYBREVANT FASPRO. Data releases highlighted CAPLYTA as a promising option for achieving remission in adults with major depressive disorder, TECVAYLI monotherapy, RYBREVANT, nipocalimab, CARVYKTI, INLEXZO and TREMFYA.
Other notable announcements include Johnson & Johnson’s agreement with the U.S. Government to improve access to medicines and lower costs, the completion of the acquisition of Halda Therapeutics, and the intent to separate its Orthopaedics business.
Johnson & Johnson will host an investor conference call today at 8:30 a.m. Eastern Time, accessible via webcast on the company’s website.
Learn more at www.jnj.com.
Contact:
Investor Relations:
investor.jnj.com
Media Relations:
media-relations@jnj.com
Source: Johnson & Johnson
